Mohand Ouidir Ouidja

Mohand Ouidir Ouidja

Auto-generated profile, based on publicly available information

Mohand Ouidir Ouidja

Cell Growth, Tissue Repair and Regeneration (CRRET), UPEC EA 4397/ERL CNRS 9215, Université Paris Est Créteil, Université Paris Est, Créteil, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BHBrandon B. Holmes
Brandon B. Holmes
SDSarah L. DeVos
Sarah L. DeVos
NKNajla Kfoury
Najla Kfoury
MLMei Li
Mei Li
RJRachel Jacks
Rachel Jacks
MDMarc I. Diamond
Marc I. Diamond
Recent experimental evidence suggests that transcellular propagation of fibrillar protein aggregates drives the progression of neurodegenerative diseases in a prion-like manner. This phenomenon is now well described in cell and animal models and involves the release of protein aggregates into the extracellular space. Free aggregates then enter neighboring cells to seed further fibrillization. The mechanism by which aggregated extracellular proteins such as tau and α-synuclein bind and enter cells to trigger intracellular fibril formation is unknown. Prior work indicates that prion protein aggregates bind heparan sulfate proteoglycans (HSPGs) on the cell surface to transmit pathologic processes. Here, we find that tau fibril uptake also occurs via HSPG binding. This is blocked in cultured cells and primary neurons by heparin, chlorate, heparinase, and genetic knockdown of a key HSPG synthetic enzyme, Ext1. Interference with tau binding to HSPGs prevents recombinant tau fibrils from inducing intracellular aggregation and blocks transcellular aggregate propagation. In vivo, a heparin mimetic, F6, blocks neuronal uptake of stereotactically injected tau fibrils. Finally, uptake and seeding by α-synuclein fibrils, but not huntingtin fibrils, occurs by the same mechanism as tau. This work suggests a unifying mechanism of cell uptake and propagation for tauopathy and synucleinopathy.

8 January 2016 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
FSFlávia V. Santa-Cecília
Flávia V. Santa-Cecília
BSBenjamin Socias
Benjamin Socias
MOMohand O. Ouidja
Mohand O. Ouidja
JSJulia E. Sepulveda-Diaz
Julia E. Sepulveda-Diaz
LALeonardo Acuña
Leonardo Acuña
Rita Raisman-VozariRita Raisman-Vozari
Rita Raisman-Vozari

4 April 2015 in Brain
Verified
Journal Article
Open access
PDF file
JSJulia Elisa Sepulveda-Diaz
Julia Elisa Sepulveda-Diaz
SNSeyedeh Maryam Alavi Naini
Seyedeh Maryam Alavi Naini
MHMinh Bao Huynh
Minh Bao Huynh
MOMohand Ouidir Ouidja
Mohand Ouidir Ouidja
CYConstantin Yanicostas
Constantin Yanicostas
DPDulce Papy-García
Dulce Papy-García
Heparan sulphate (glucosamine) 3-O-sulphotransferase 2 (HS3ST2, also known as 3OST2) is an enzyme predominantly expressed in neurons wherein it generates rare 3-O-sulphated domains of unknown functions in heparan sulphates. In Alzheimer’s disease, heparan sulphates accumulate at the intracellular level in disease neurons where they co-localize with the neurofibrillary pathology, while they persist at the neuronal cell membrane in normal brain. However, it is unknown whether HS3ST2 and its 3-O-sulphated heparan sulphate products are involved in the mechanisms leading to the abnormal phosphorylation of tau in Alzheimer’s disease and related tauopathies. Here, we first measured the transcript levels of all human heparan sulphate sulphotransferases in hippocampus of Alzheimer’s disease (n = 8; 76.8 ± 3.5 years old) and found increased expression of HS3ST2 (P < 0.001) compared with control brain (n = 8; 67.8 ± 2.9 years old). Then, to investigate whether the membrane-associated 3-O-sulphated heparan sulphates translocate to the intracellular level under pathological conditions, we used two cell models of tauopathy in neuro-differentiated SH-SY5Y cells: a tau mutation-dependent model in cells expressing human tau carrying the P301L mutation hTauP301L, and a tau mutation-independent model in where tau hyperphosphorylation is induced by oxidative stress. Confocal microscopy, fluorescence resonance energy transfer, and western blot analyses showed that 3-O-sulphated heparan sulphates can be internalized into cells where they interact with tau, promoting its abnormal phosphorylation, but not that of p38 or NF-κB p65. We showed, in vitro, that the 3-O-sulphated heparan sulphates bind to tau, but not to GSK3B, protein kinase A or protein phosphatase 2, inducing its abnormal phosphorylation. Finally, we demonstrated in a zebrafish model of tauopathy expressing the hTauP301L, that inhibiting hs3st2 (also known as 3ost2) expression results in a strong inhibition of the abnormally phosphorylated tau epitopes in brain and in spinal cord, leading to a complete recovery of motor neuronal axons length (n = 25; P < 0.005) and of the animal motor response to touching stimuli (n = 150; P < 0.005). Our findings indicate that HS3ST2 centrally participates to the molecular mechanisms leading the abnormal phosphorylation of tau. By interacting with tau at the intracellular level, the 3-O-sulphated heparan sulphates produced by HS3ST2 might act as molecular chaperones allowing the abnormal phosphorylation of tau. We propose HS3ST2 as a novel therapeutic target for Alzheimer’s disease.

14 June 2018 in FEBS Letters
Verified
Journal Article
Closed access
AMAuriane Maïza
Auriane Maïza
SCSandrine Chantepie
Sandrine Chantepie
CVCecilia Vera
Cecilia Vera
AFAlexandre Fifre
Alexandre Fifre
MHMinh Bao Huynh
Minh Bao Huynh
DPDulce Papy‐Garcia
Dulce Papy‐Garcia

4 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMinh Bao Huynh
Minh Bao Huynh
MOMohand Ouidir Ouidja
Mohand Ouidir Ouidja
SCSandrine Chantepie
Sandrine Chantepie
GCGilles Carpentier
Gilles Carpentier
AMAuriane Maïza
Auriane Maïza
DPDulce Papy-García
Dulce Papy-García
Glycosaminoglycans (GAGs), including heparan sulfates and chondroitin sulfates, are major components of the extracellular matrix. Upon interacting with heparin binding growth factors (HBGF), GAGs participate to the maintaintenance of tissue homeostasis and contribute to self-healing. Although several processes regulated by HBGF are altered in Alzheimer’s disease, it is unknown whether the brain GAG capacities to bind and regulate the function of HBGF or of other heparin binding proteins, as tau, are modified in this disease. Here, we show that total sulfated GAGs from hippocampus of Alzheimer’s disease have altered capacities to bind and potentiate the activities of growth factors including FGF-2, VEGF, and BDNF while their capacity to bind to tau is remarkable increased. Alterations of GAG structures and capacities to interact with and regulate the activity of heparin binding proteins might contribute to impaired tissue homeostasis in the Alzheimer’s disease brain.

24 January 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLSonia Lehri-Boufala
Sonia Lehri-Boufala
MOMohand-Ouidir Ouidja
Mohand-Ouidir Ouidja
VBVéronique Barbier-Chassefière
Véronique Barbier-Chassefière
EHEmilie Hénault
Emilie Hénault
RRRita Raisman-Vozari
Rita Raisman-Vozari
CMChristophe Morin
Christophe Morin
The causes of Parkinson disease (PD) remain mysterious, although some evidence supports mitochondrial dysfunctions and α-synuclein accumulation in Lewy bodies as major events. The abnormal accumulation of α-synuclein has been associated with a deficiency in the ubiquitin-proteasome system and the autophagy-lysosomal pathway. Cathepsin D (cathD), the major lysosomal protease responsible of α-synuclein degradation was described to be up-regulated in PD model. As glycosaminoglycans (GAGs) regulate cathD activity, and have been recently suggested to participate in PD physiopathology, we investigated their role in α-synuclein accumulation by their intracellular regulation of cathD activity. In a classical neuroblastoma cell model of PD induced by MPP+, the genetic expression of GAGs-biosynthetic enzymes was modified, leading to an increase of GAGs amounts whereas intracellular level of α-synuclein increased. The absence of sulfated GAGs increased intracellular cathD activity and limited α-synuclein accumulation. GAGs effects on cathD further suggested that specific sequences or sulfation patterns could be responsible for this regulation. The present study identifies, for the first time, GAGs as new regulators of the lysosome degradation pathway, regulating cathD activity and affecting two main biological processes, α-synuclein aggregation and apoptosis. Finally, this opens new insights into intracellular GAGs functions and new fields of investigation for glycobiological approaches in PD and neurobiology.